|
| Case Report |
From the Departments of Medicine (Loewen, Hill), Radiology (Hudon), Clinical Neurosciences (Hudon, Hill) and Community Health Sciences (Hill), Faculty of Medicine, University of Calgary, Calgary, Alta.
| Abstract |
|---|
|
|
|---|
|
The patient had been using Afrin, a nasal spray that contains oxymetazoline, regularly for the previous 6 months. Although she was using the medication at recommended daily dosages (23 sprays twice daily), she was using it consistently. Two weeks before presentation she had noticed a pattern of headache starting 20 minutes after use of the nasal spray. The index event had occurred immediately after its use.
Use of the nasal spray was discontinued. Narcotic analgesics reduced the pain, but the nausea and vomiting responded to ondansetron only. The patient had no improvement in her headache with nimodipine, a calcium-channel antagonist that causes dilatation of arterial smooth muscle. Repeat lumbar puncture was done in the supine position at discharge and demonstrated an opening pressure of 19 cm H2O. Two weeks after discharge the headache had nearly resolved. A repeat angiogram at 6 weeks showed complete resolution of most areas of arterial narrowing (Fig. 1D).
| Comments |
|---|
|
|
|---|
Cerebral vasoconstriction has been reported with cerebral vascular events, especially subarachnoid hemorrhage; as a complication of disease states such as porphyric encephalopathy, pheochromocytoma and eclampsia; and as a result of exogenously administered blood products or drugs such as intravenous immunoglobulin in GuillainBarré syndrome, angiographic contrast medium, amphetamines, serotonergic drugs and methylenedioxymethamphetamine (ecstasy).1,2 The patient in our case was taking sertraline concurrently with oxymetazoline. Selective serotonin reuptake inhibitors have been associated with reversible segmental cerebral vasoconstriction and stroke. The patient's headache improved after cessation of the oxymetazoline alone, and thus it appears to have been the primary agent in her cerebral vasoconstriction. However, an interaction with sertraline could also have played a role.
Oxymetazoline is a selective
2A-adrenergic receptor agonist. It is used as a topical vasoconstrictor for rhinitis. Adverse effects include rebound congestion, hypertension, palpitations and headaches. There have been case reports of stroke associated with oxymetazoline, but none described cerebral vasoconstriction.3,4 This case report illustrates that oxymetazoline can cause reversible segmental cerebral vasoconstriction, resulting in thunderclap headache.
Possible mechanisms of stroke with sympathomimetics include acute hypertension, hemorrhage, vasospasm, vasospasm-induced thrombosis and angiitis. In this case, because of the reversible changes, we believe the patient had cerebral vasospasm, but a concurrent arteritis is possible given the long duration of exposure. Since resolution of this arteritis with cessation of the drug would be expected, the patient will be monitored for recurrence of clinical symptoms.
This case highlights a potential systemic toxic effect of oxymetazoline nasal spray, specifically reversible segmental cerebral vasoconstriction causing thunderclap headache. Patients presenting with thunderclap headache should be questioned about their use of predisposing medications including over-the-counter nasal decongestants. In addition to cerebral angiography, CT and MRI angiography and transcranial doppler have been used to diagnose intracerebral vasoconstriction in other cases. Abstinence from the offending drug is the main therapy, although calcium-channel blockers may also have a therapeutic role.
| Footnotes |
|---|
Contributors: Andrea Loewen wrote the first draft of the manuscript with input and editorial assistance from Mark Hudon and Michael Hill. All authors approved the final manuscript for publication.
Dr. Hill was supported by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Alberta. This article was presented at the Canadian Society for Internal Medicine, Quebec City, Quebec, in June 2004.
Competing interests: None declared.
Correspondence to: Michael D. Hill, Assistant Professor, Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Foothills Hospital, Rm. 1242A, 140329th St. NW, Calgary AB T2N 2T9; fax 403 283-2270; michael.hill{at}calgaryhealthregion.ca
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Ducros, M. Boukobza, R. Porcher, M. Sarov, D. Valade, and M.-G. Bousser The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients Brain, December 1, 2007; 130(12): 3091 - 3101. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||